382 related articles for article (PubMed ID: 10816741)
1. [Melarsoprol].
Simon F
Med Trop (Mars); 1999; 59(4):331-2. PubMed ID: 10816741
[No Abstract] [Full Text] [Related]
2. [In vivo resistance to strains of Trypanosoma rhodesiense, Mozambique, 1985].
Pérez Martín O; Lastre González M; Urban M; Shwalbach J
Rev Cubana Med Trop; 1991; 43(3):189-93. PubMed ID: 9768188
[TBL] [Abstract][Full Text] [Related]
3. Veterinary link to drug resistance in human African trypanosomiasis?
Barrett MP
Lancet; 2001 Aug; 358(9282):603-4. PubMed ID: 11530144
[No Abstract] [Full Text] [Related]
4. Randomized, controlled trial of treatments for second-stage sleeping sickness.
Woodrow CJ; Abel PM; Krishna S
J Infect Dis; 2007 Aug; 196(4):650-1. PubMed ID: 17624857
[No Abstract] [Full Text] [Related]
5. Current chemotherapy of human African trypanosomiasis.
Docampo R; Moreno SN
Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544
[TBL] [Abstract][Full Text] [Related]
6. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
Maina N; Maina KJ; Mäser P; Brun R
Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860
[TBL] [Abstract][Full Text] [Related]
7. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.
Nok AJ
Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807
[TBL] [Abstract][Full Text] [Related]
8. [Three patients with African sleeping sickness following a visit to Tanzania].
Mendonça Melo M; Rasica M; van Thiel PP; Richter C; Kager PA; Wismans PJ
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2552-6. PubMed ID: 12532670
[TBL] [Abstract][Full Text] [Related]
9. The treatment of human African trypanosomiasis.
Pépin J; Milord F
Adv Parasitol; 1994; 33():1-47. PubMed ID: 8122565
[No Abstract] [Full Text] [Related]
10. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
[TBL] [Abstract][Full Text] [Related]
11. The phenomenon of treatment failures in Human African Trypanosomiasis.
Brun R; Schumacher R; Schmid C; Kunz C; Burri C
Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
[TBL] [Abstract][Full Text] [Related]
12. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA
Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099
[TBL] [Abstract][Full Text] [Related]
13. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility.
Alibu VP; Richter C; Voncken F; Marti G; Shahi S; Renggli CK; Seebeck T; Brun R; Clayton C
Mol Biochem Parasitol; 2006 Mar; 146(1):38-44. PubMed ID: 16343658
[TBL] [Abstract][Full Text] [Related]
14. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
[TBL] [Abstract][Full Text] [Related]
15. Human African trypanosomiasis: diagnosis, relapse and survival after severe melarsoprol-induced encephalopathy.
Checkley AM; Pepin J; Gibson WC; Taylor MN; Jäger HR; Mabey DC
Trans R Soc Trop Med Hyg; 2007 May; 101(5):523-6. PubMed ID: 17270227
[TBL] [Abstract][Full Text] [Related]
16. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
Gehrig S; Efferth T
Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
[TBL] [Abstract][Full Text] [Related]
17. Gambian trypanosomiasis and synergism between melarsoprol and eflornithine: first case report.
Simarro PP; Asumu PN
Trans R Soc Trop Med Hyg; 1996; 90(3):315. PubMed ID: 8758090
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.
Wenzler T; Yang S; Braissant O; Boykin DW; Brun R; Wang MZ
Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303
[TBL] [Abstract][Full Text] [Related]
19. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis.
Lejon V; Roger I; Mumba Ngoyi D; Menten J; Robays J; N'siesi FX; Bisser S; Boelaert M; Büscher P
Clin Infect Dis; 2008 Jul; 47(1):15-22. PubMed ID: 18494605
[TBL] [Abstract][Full Text] [Related]
20. Eflornithine for the treatment of human African trypanosomiasis.
Burri C; Brun R
Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
